1. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014) Authors: Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A. Journal: Cancer Issue: Volume 120:Issue 8(2014) Page Start: 1145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib. Issue 8 (5th February 2014) Authors: Reckamp, Karen L.; Giaccone, Giuseppe; Camidge, D. Ross; Gadgeel, Shirish M.; Khuri, Fadlo R.; Engelman, Jeff A.; Koczywas, Marianna; Rajan, Arun; Campbell, Alicyn K.; Gernhardt, Diana; Ruiz‐Garcia, Ana; Letrent, Stephen; Liang, Jane; Taylor, Ian; O'Connell, Joseph P.; Jänne, Pasi A. Journal: Cancer Issue: Volume 120:Issue 8(2014) Page Start: 1145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗